Sonidegib (NVP-LDE225)

For research use only. Not for use in humans.

目录号：S2151 别名： Erismodegib 中文名称：索尼德吉

Sonidegib (NVP-LDE225) Chemical Structure

CAS No. 956697-53-3

Sonidegib (Erismodegib, NVP-LDE225)是一种Smoothened(Smo)拮抗剂，抑制Hedgehog (Hh)信号通路，无细胞试验中IC50分别为1.3 nM (小鼠)和2.5 nM(人)。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1727.35	现货
5mg	RMB 1219.02	现货
10mg	RMB 2235.15	现货
25mg	RMB 3844.77	现货
100mg	RMB 9803.43	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Sonidegib (NVP-LDE225)发表文献49篇：

Nat Med, 2014, 20(7):732-40

PubMed: 24973920 ( click the link to review the publication )

Sci Rep, 2022, 12(1):7

PubMed: 34997030 ( click the link to review the publication )

Blood, 2021, blood.2020010207

PubMed: 34424959 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.13097

PubMed: 34482626 ( click the link to review the publication )

Sci Rep, 2021, 11(1):17665

PubMed: 34480080 ( click the link to review the publication )

Reprod Sci, 2021, 10.1007/s43032-021-00731-y

PubMed: 34642915 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 30(3):771-782

PubMed: 31968252 ( click the link to review the publication )

Cells, 2020, 10(1)E53

PubMed: 33396427 ( click the link to review the publication )

Carcinogenesis, 2020, 41(7):993-1004

PubMed: 31740922 ( click the link to review the publication )

J Clin Invest, 2020, 130(8):4006-4018

PubMed: 32568216 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz089

PubMed: 31111916 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31658643 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31835472 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):289

PubMed: 31547878 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 115:105578

PubMed: 31374250 ( click the link to review the publication )

PLoS One, 2019, 14(12):e0226570

PubMed: 31860685 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:7477-7488

PubMed: 31686853 ( click the link to review the publication )

Med Sci Monit, 2019, 25:8579-8586

PubMed: 31724562 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1576

PubMed: 32038250 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4010

PubMed: 30275454 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(4):893-902

PubMed: 29138054 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )
Endocrinology, 2018, 159(2):579-596

PubMed: 29211850 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190070

PubMed: 29293549 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):142

PubMed: 29396391 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

Br J Cancer, 2017, 116(11):1425-1435

PubMed: 28441382 ( click the link to review the publication )

Cancer Discov, 2017,

PubMed: 28923910 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

, 2017, 49(11):e396

PubMed: 29147013 ( click the link to review the publication )

Stem Cells Int, 2017, 2017:7507380

PubMed: 28243259 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7049-7058

PubMed: 27758883 ( click the link to review the publication )

Cell Death Dis, 2016, 7(9):e2376

PubMed: 27899820 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Int J Oncol, 2016, 48(2):801-12

PubMed: 26676886 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0150836

PubMed: 26938241 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4686-97

PubMed: 26124204 ( click the link to review the publication )

Mol Cancer, 2015, 10.1186/s12943-015-0345-x

PubMed: ( click the link to review the publication )

J Hematol Oncol, 2015, 8:63

PubMed: 26048374 ( click the link to review the publication )

Oncogene, 2015, 34(29):3770-9

PubMed: 25241898 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.267

PubMed: 26189795 ( click the link to review the publication )

Mol Cancer, 2015, 14:72

PubMed: 25889650 ( click the link to review the publication )

Br J Cancer, 2014, 111(6):1168-7

PubMed: 25093491 ( click the link to review the publication )

Mol Pharmacol, 2014, 83(5):1020-9

PubMed: 23448715 ( click the link to review the publication )

Oncotarget, 2014, 5(7):1926-41

PubMed: 24732172 ( click the link to review the publication )
Nat Chem Biol, 2013, 9(4):247-9

PubMed: 23416332 ( click the link to review the publication )

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述

Sonidegib (Erismodegib, NVP-LDE225)是一种Smoothened(Smo)拮抗剂，抑制Hedgehog (Hh)信号通路，无细胞试验中IC50分别为1.3 nM (小鼠)和2.5 nM(人)。Phase 3。

特性

LDE225 是具有高效性和选择性的使平滑的拮抗剂

靶点

Smo (mouse) ^[1] (Cell-free assay)	Smo (human) ^[1] (Cell-free assay)
1.3 nM	2.5 nM

体外研究

Sonidegib (Erismodegib, NVP-LDE225)可在0.6-0.8μM剂量上抑制1nM-25nM Hh激动剂Ag1.5 处理的TM3荧光报告细胞系。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A2780ip2	MkjMR5l1d3irY3n0fUBie3OjeR?=	MVv+NVAh\|ryP			MUjJR\|UxRTF{IN88US=>	NYrNXmFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OVM{PTVpPkKyOVU{OzV3PD;hQi=>
A2780cp20	MXXDfZRwgGmlaYT5JIF{e2G7	NEXJZmN,OTBizszN			MX7JR\|UxRTdwNTFOwG0>	M3TXNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUWzN\|U2Lz5{MkW1N\|M2PTxxYU6=
SKOV3ip1	MXTDfZRwgGmlaYT5JIF{e2G7	M2D3NZ4yOCEQvF2=			NIPJcmdKSzVyPUK0JO69VQ>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV3M{O1OUc,OjJ3NUOzOVU9N2F-
SKOV3TRip2	NXrlfGh6S3m2b4jpZ4l1gSCjc4PhfS=>	Ml\RglExKM7:TR?=			M4\GbmlEPTB;MUKg{txO	MkHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NUOzOVUoRjJ{NUWzN\|U2RC:jPh?=
HeyA8	NIPmeY9EgXSxeHnjbZR6KGG\|c3H5	MU\+NVAh\|ryP			NVLEWXdJUUN3ME2xPEDPxE1?	MmXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NUOzOVUoRjJ{NUWzN\|U2RC:jPh?=
HeyA8MDR	NIT6cpdEgXSxeHnjbZR6KGG\|c3H5	NUXWc4xWhjFyIN88US=>			MV\JR\|UxRThizszN	M3PQVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUWzN\|U2Lz5{MkW1N\|M2PTxxYU6=
OS5	NUj4R5VIT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NV\GdmJbhjVizszN			M1SzbZJm\HWlZYOgeIhmKHC{b3zp[oVz[XSrb36=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ2M{W5OUc,OjN{NEO1PVU9N2F-
OS18	MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXr+OUDPxE1?			NHLpcZVz\WS3Y3XzJJRp\SCycn;sbYZmemG2aX;u	MmP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NEO1PVUoRjJ\|MkSzOVk2RC:jPh?=
Glioblastoma initiating cells	NUThc45NS3m2b4jpZ4l1gSCjc4PhfS=>	NHW3VVF,OTBizszN			NFPHVGJKdmirYnn0d{BE\WyuIG\pZYJqdGm2eR?=	NUnTc4VzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PFI3PzFpPkKzOFgzPjdzPD;hQi=>
Glioblastoma initiating cells	MXXGeY5kfGmxbjDhd5NigQ>?	M2HSPJ4yOCEQvF2=			MlLVbY5pcWKrdIOgcoV2em:\|cHjldoUh\m:{bXH0bY9v	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR6Mk[3NUc,OjN2OEK2O\|E9N2F-
Glioblastoma initiating cells	MXnDfZRwgGmlaYT5JIF{e2G7	NVjVdmI3hjFyIN88US=>			NILQd\|hqdmS3Y3XzJIFxd3C2b4Ppdy=>	MkjXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OEK2O\|EoRjJ\|NEiyOlcyRC:jPh?=
Glioblastoma initiating cells	MmjLSpVv[3Srb36gZZN{[Xl?	NIC2ZXd,OTBizszN			NWf0RVVy\G:5boLl[5Vt[XSnczD0bIUhW0iKIIPp[45idGmwZzDwZZRpf2G7	Ml7UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OEK2O\|EoRjJ\|NEiyOlcyRC:jPh?=
Glioblastoma initiating cells	MXjGeY5kfGmxbjDhd5NigQ>?	NIOwUW1,OTBizszN			NWC5SnBqUW6qaXLpeJMhfGinIFX4dJJme3Orb36gc4YhT2WwZYOgTY53d2y4ZXSgbY4hVWGrboThbY5qdmdiUHz1dolxd3SnbnP5	M{X5Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEiyOlcyLz5{M{S4NlY4OTxxYU6=
Glioblastoma initiating cells	M2XGWmZ2dmO2aX;uJIF{e2G7	NFHuVYF,OTBizszN			M2X0TWlvcGmkaYTzJG1wfGmuaYT5MEBKdn[jc3nvckwh[W6mIF3p[5JifGmxbh?=	M3q4[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEiyOlcyLz5{M{S4NlY4OTxxYU6=
LOX IMVI	NVzONWxETnWwY4Tpc44h[XO\|YYm=	NXH2dFZ7OTBizszN		MXLEUXNQ	NEjsTVlqdmirYnn0d{BJ\WSpZXjv[{1IVElicHH0bJdigQ>?	M3e1SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUO1PVI2Lz5{M{mzOVkzPTxxYU6=
UACC 257	NVy2[ZBHTnWwY4Tpc44h[XO\|YYm=	MlLCNVAh\|ryP		MVjEUXNQ	NV3BRoJScW6qaXLpeJMhUGWmZ3Xoc4cuT0yLIIDheIh4[Xl?	M4Drd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUO1PVI2Lz5{M{mzOVkzPTxxYU6=
LOX IMVI	NH;KOYNHfW6ldHnvckBie3OjeR?=	MXixNEDPxE1?		M4fkZWROW09?	MXfpcoR2[2W\|IFexJINmdGxiY4njcIUh[XK{ZYP0	NWfsUVRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|U6OjVpPkKzPVM2QTJ3PD;hQi=>
UACC 257	M3K1dWZ2dmO2aX;uJIF{e2G7	MVixNEDPxE1?		NHi0WIxFVVOR	NVXibGJGcW6mdXPld{BIOSClZXzsJIN6[2ynIHHydoV{fA>?	NVLielJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|U6OjVpPkKzPVM2QTJ3PD;hQi=>
LOX IMVI	NX\qSmlrS3m2b4jpZ4l1gSCjc4PhfS=>	M1T0elExKM7:TR?=		NW\lWFQzTE2VTx?=	MVnk[YNz\WG\|ZYOgeJVud3JiY3XscEB3cWGkaXzpeJk>	NWD6bVI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|U6OjVpPkKzPVM2QTJ3PD;hQi=>
UACC 257	MnPjR5l1d3irY3n0fUBie3OjeR?=	MkL2NVAh\|ryP		NGDUUItFVVOR	MmPW[IVkemWjc3XzJJR2dW:{IHPlcIwhfmmjYnnsbZR6	M176[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUO1PVI2Lz5{M{mzOVkzPTxxYU6=
LOX IMVI	NIPhWZBCeG:ydH;zbZMh[XO\|YYm=	M2HBO\|ExKM7:TR?=		NXzWXXBVTE2VTx?=	NHjWTVNqdmS3Y3XzJIFxd3C2b4Ppdy=>	NGT3W4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mzOVkzPSd-MkO5N\|U6OjV:L3G+
UACC 257	NFfZd4RCeG:ydH;zbZMh[XO\|YYm=	NUiwPG1HOTBizszN		NVrKXG85TE2VTx?=	NGnR[3dqdmS3Y3XzJIFxd3C2b4Ppdy=>	NW\mOXVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|U6OjVpPkKzPVM2QTJ3PD;hQi=>
ACHN	NYjofYF6T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M33IZZ42KM7:TR?=		MkX3SG1UVw>?	NXi1[XVtUUN3ME2yMVPjiIoQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB7M{S5NUc,OjVyOUO0PVE9N2F-
769-P	NWr3W4x{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmW4glUh\|ryP		MUXEUXNQ	MXvJR\|UxRTJvM,MAje69VQ>?	M3[xTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEmzOFkyLz5{NUC5N\|Q6OTxxYU6=
786-O	MmTJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MV3+OUDPxE1?		MnziSG1UVw>?	NXjN[VJQUUN3ME2yMVPjiIoQvF2=	NXvQ[plZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwPVM1QTFpPkK1NFk{PDlzPD;hQi=>
786-O SuR	MoXqS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXn+OUDPxE1?		MoPESG1UVw>?	MVfJR\|UxRTJvM,MAje69VQ>?	Mke5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyOUO0PVEoRjJ3MEmzOFkyRC:jPh?=
SP53	Mmf3SpVv[3Srb36gZZN{[Xl?	NYDmfZRUOzBizszN		NXj2[2JsTE2VTx?=	NIPLPZVqdmirYnn0d{Bk\WyuIHHkbIV{cW:wIHHu[EBucWe{YYTpc44>	NYe4cmZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4PFU3ODhpPkK2PFg2PjB6PD;hQi=>
SP53	MkTYSpVv[3Srb36gZZN{[Xl?	NUXWWoFbOzBizszN		NGf2NW9FVVOR	M3PmcolvcGmkaYTzJJRp\SCYTFG0MY1m\GmjdHXkJGZCUyC\|aXfuZYxqdmdicHH0bJdigQ>?	NYmz[Jg3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4PFU3ODhpPkK2PFg2PjB6PD;hQi=>
HS5	MUjGeY5kfGmxbjDhd5NigQ>?	M{G3[lMxKM7:TR?=		MXjEUXNQ	M1;kR4lvcGmkaYTzJINmdGxiYXTo[ZNqd25iYX7kJI1q\3KjdHnvci=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh6NU[wPEc,OjZ6OEW2NFg9N2F-
HS27a	MXzGeY5kfGmxbjDhd5NigQ>?	M4W2UlMxKM7:TR?=		NH\KdppFVVOR	NIfqNJJqdmirYnn0d{Bk\WyuIHHkbIV{cW:wIHHu[EBucWe{YYTpc44>	NYntNZp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4PFU3ODhpPkK2PFg2PjB6PD;hQi=>
SP53	NYLXRYhkS3m2b4jpZ4l1gSCjc4PhfS=>	MlLqN\|Ah\|ryP		MmTrSG1UVw>?	NIPTXG9qdmS3Y3XzJIF2fG:yaHHnfS=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjh6NU[wPEc,OjZ6OEW2NFg9N2F-
Jeko	MljUR5l1d3irY3n0fUBie3OjeR?=	NGPKSoM{OCEQvF2=		NWrib\|Y{TE2VTx?=	NG\DT5JqdmS3Y3XzJIF2fG:yaHHnfS=>	NVrQTVZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4PFU3ODhpPkK2PFg2PjB6PD;hQi=>
U2OS	NXL1NWNqTnWwY4Tpc44h[XO\|YYm=		M4CwXVIhcHK\|		MVXEbZNxdGGlZX3lcpQhd2ZiW{PIYYN6[2yxcHHtbY5mKG[{b32ge4lt\CC2eYDlJHNudyCneIDy[ZN{\WRiaX6gWVJQWyClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCNaTC9JFAvODB4IN88UU4>	MnrNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkO1NlIoRjJ\|ME[zOVIzRC:jPh?=
NIH/3T3	NYK3bnNoTnWwY4Tpc44h[XO\|YYm=				M2\WNWlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTlnIM\|NVOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCVbX:gZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIFfsbUBuWk6DIHX4dJJme3Orb36gZpkhWlRvUFPSJI1mfGixZDygTWM2OCB;IECuNFA1PCEQvF2u	Ml7KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MUC1PVEoRjJ5OEGwOVkyRC:jPh?=
NIH/3T3	MU\GeY5kfGmxbjDhd5NigQ>?				M1zBTWlvcGmkaYTpc44hd2ZiaHXk[4Vpd2dic3nncoFtcW6pIIDheIh4[XliaX6gcY92e2ViTlnIM\|NVOyClZXzsd{Bp[XKkb4LpcochW22xIFS0O\|dJKG23dHHueEBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gS4xqKG2UTlGg[ZhxemW\|c3nvckBjgSCUVD3QR3IhdWW2aH;kMEBKSzVyIE2gNE4xOjJ5IN88UU4>	NGXvO5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{ixNFU6OSd-Mke4NVA2QTF:L3G+
NIH/3T3	MXjGeY5kfGmxbjDhd5NigQ>?		M4TWOVI1KGi{cx?=		Mnz3TY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEK0JIhzeyCkeTDHcIku\HWjbDDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEmFNUCgQUAxNjByNjFOwG0v	NWHF[GJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVA2QTFpPkK3PFExPTlzPD;hQi=>
TM3	MmP5SpVv[3Srb36gZZN{[Xl?		NUDuWGdzPDhiaILz		M1rLd2lvcGmkaYTpc44hd2ZiSHigd4lodmGuaX7nJJBifGi5YYmgbY4hdW:3c3WgWG0{KGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEeuaUGg[4Vv\SCneIDy[ZN{cW:wIHHmeIVzKDR6IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTBiPTCwMlAxOTJizszNMi=>	NHL1S3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm3OlIyPSd-Mk[5O\|YzOTV:L3G+
NIH3T3	NEL0VlBHfW6ldHnvckBie3OjeR?=		M2[3[VQ5KGi{cx?=		NHzYUotKdmirYnn0bY9vKG:oIGPITEB{cWewYXzpcocheGG2aIfhfUBqdiCvb4Xz[UBPUUh\|VEOgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhPDhiaILzJIJ6KEeuaT3seYNq\mW{YYPlJJJmeG:{dHXyJIF{e2G7LDDJR\|UxKD1iMD6wNFU2KM7:TT6=	NVXFOpFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxO\|Y{QTZpPkK0NVc3Ozl4PD;hQi=>
NIH3T3	MorHSpVv[3Srb36gZZN{[Xl?		NUj4eZVQPDhiaILz		NHzQRYRKdmirYnn0bY9vKG:oIGPvcolkNWmwZIXj[YQhcGWmZ3Xoc4che2mpbnHscIlv\yCrbjDtc5V{\SCQSVizWFMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IFfsbU1tfWOrZnXyZZNmKHKncH;yeIVzKGG\|c3H5MEBKSzVyIE2gNE4xODV3IN88UU4>	M1\FSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEKwOVU1Lz5{NkiyNFU2PDxxYU6=
NIH/3T3	NHLOZWtHfW6ldHnvckBie3OjeR?=				NUnGNW8{UW6qaXLpeIlwdiCxZjDo[YRo\WixZzDzbYdv[WyrbnegdIF1cHejeTDlfJBz\XO\|ZXSgbY4hdW:3c3WgUmlJNzOWMzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGinZHflbI9oNWmwZIXj[YQhT2yrLUKgZYNkfW23bHH0bY9vKGG2IITpdEBw\iCycnntZZJ6KGOrbHnhJIJ6KESDUFmgd5RicW6rbnegZoF{\WRiY3;u[o9k[WxibXnjdo9{[2:yaXOgZY5idHm\|aYO=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzMEW5NUc,Ojd6MUC1PVE9N2F-
NIH/3T3	MnvNSpVv[3Srb36gZZN{[Xl?				MnPLTY5pcWKrdHnvckBw\iCqZXTn[Yhw\yC\|aXfuZYxqdmdicHH0bJdigSCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gbIVl\2Wqb3etbY5lfWOnZDDTcY8uTUeIUDDjbYxq[XK7IITyZY5{dG:lYYTpc44h[nliRFHQTUB{fGGrbnnu[{Bj[XOnZDDjc45nd2OjbDDtbYNzd3Olb4DpZ{BidmGueYPpdy=>	M1TUWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEGwOVkyLz5{N{ixNFU6OTxxYU6=
MG 63 (6-TG R)	M1rMVJFJXFNiYYPzZZk>				MYjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=>	MkTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	MnXFdWhVWyCjc4PhfS=>				MX;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	M3v6ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	NVzjXpB4eUiWUzDhd5NigQ>?				NV7NO4xReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	M2LOOZFJXFNiYYPzZZk>				NV7sSVI1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	MVfxTHRUKGG\|c3H5				NGDrcmdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	NVXEWIl5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	MmDMdWhVWyCjc4PhfS=>				M1XVdZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	M{T1d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	MX3xTHRUKGG\|c3H5				MkDRdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	NFfZcFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NWDjXYlkeUiWUzDhd5NigQ>?				NHLmOFZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	NUK0Ool7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	MV;xTHRUKGG\|c3H5				NXTrS2VXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	NFHWR4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	M1v2TZFJXFNiYYPzZZk>				NFf0U2FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	MkDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MUjxTHRUKGG\|c3H5				NVjuPIRKeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	MXPxTHRUKGG\|c3H5				M{PHeJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	M1yzNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Bcl2 / c-myc / Cyclin D1 / pERK / ERK / pJNK / JNK / Caspase 3 / Cleaved caspase 3 ; PubMed: 22821765 Blood Immunoblot experiment of protein lysate from OPM1 cells treated with NVP-LDE225 (5μM) for 12, 24, and 36 hours and fractionated by electrophoresis and stained with different Abs as shown in figure (left). Cells were treated with different concentrations o䲧疝Ỵ疞㧀疜膉痘瘿⟸෕ᾰƌ෕Ð㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸 Gli-1 / Gli-2 / p-Akt / Akt; PubMed: 25093491 Br J Cancer Western blot analysis on total cell lysates from renal cancer cell lines treated with NVP-LDE225 at different concentrations. Densitometric measurements were normalised to β-actin and reported under western blot images. pp70S6K / P70s6k; PubMed: 25093491 Br J Cancer Percentage of survival of 786-O, 786-O SuR, and 769-P renal cancer cell lines treated with NVP-LDE225 and everolimus or their combination, as measured by the MTT assay. Data represent the mean (±s.d.) of three independent experiments, each performed in tr䲧疝Ỵ疞㧀疜膉痘瘿뙠ෆᾰƌෆĀ㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋𢡄�෋䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲� p-p130CAS / p130CAS / p-FAK / FAK / p-Paxillin / Paxillin; PubMed: 25093491 Br J Cancer Western blot analysis of total cell lysates from 786-O, 786-O SuR, and 769-P human renal cancer cell lines treated with NVP-LDE225 (2.5 μm), everolimus (1 μm), and their combination. Densitometric measurements were normalised to β-actin and reported under䲧疝Ỵ疞㧀疜膉痘	22821765 25093491
Immunofluorescence	GLI1; PubMed: 22821765 Blood U266 were cultured in the presence of control medium or NVP-LDE225 (5μM) for 24 hours. Immunocytochemical analysis was assessed using anti-Gli1 Ab, and 4,6-diamidino-2-phenylindole was used to stain nuclei. The cells were analyzed using an epifluorescence䲧疝Ỵ疞㧀疜膉痘瘿⟸෕ᾰƌ෕Ð㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣痖뙠ෆ𢡄뙤ෆ	22821765

体内研究

Sonidegib (Erismodegib, NVP-LDE225)与小鼠，大鼠以及人源的血浆蛋白有很强的结合能力(>99%)，同时与狗和猴子的血浆蛋白有适度的结合，结合能力分别是77 %和 85%。PAMPA 实验证明LDE225能够达到90.8%的渗透性。在梯度稀释的试验中，LDE225在临床物种上显示出很好的口服药效率，其生物药效率在69%到102%之间。LDE225呈弱碱性，pK_a只有4.20，同时它的水溶性也相对较弱。LDE225被证明具有剂量依赖的抗肿瘤活性。给药剂量在5 mg/kg/天，一天一次时，LDE225明显抑制肿瘤生长，与33%的T/C值相一致。给药剂量在10 mg/kg/天，一天一次和 20 mg/kg/天，一天一次时，LDE225促使肿瘤退化的效果分别达到51%和83%。Gli1 mRNA抑制性与LDE225介导的肿瘤与血浆接触有关。在肿瘤移植的动物模型中，经过四天的给药处理，LDE225能够成功地穿过血脑屏障导致肿瘤生长受抑制^[1]。LDE225能够使Rip1-Tag2小鼠中的肿瘤体积明显减少95.7%。LDE225减少LDE225给药处理小鼠的间质状标志基因的表达^[2]。

细胞实验： ^[1]	- 合并 Cell lines: TM3Hh12 细胞 Concentrations: 0 μM -10 μM Incubation Time: 30 分钟 Method: LDE225 用DMSO连续稀释后加入空的分析平板中。TM3Hh12 细胞 (TM3 细胞含有Hh的应答报告基因元件pTA-8xGli-Luc) 用含有5%的马血清，2.5%的胎牛血清(FBS)和15 mM HEPES, pH 7.3的F12 Ham’s/DMEM (1:1)培养基培养。收集细胞时用胰酶消化，然后用含有5%的马血清和15 mM HEPES, pH 7.3的F12 Ham’s/DMEM (1:1)培养基重悬，接着分铺到分析板中。然后加入LDE225在37 °C ，5% CO₂的培养箱中大约孵育30分钟。接着加入1 nM 和25 nM 的Ag1.5到分析平板中，37 °C ，5% CO₂的条件下培养。48小时后，向平板中加入Bright-Glo 或者 MTS试剂，测量492纳米下的荧光值或者吸收峰。通过MTS法检测Gli-驱动荧光素酶发光或吸光度信号，对浓度取Log（10）值做由非线性回归曲线，确定IC 50值。数据处理使用R统计软件包。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 采用无胸腺裸小鼠建立原位Ptch^+/-p53^-/-髓母细胞瘤同种异体移植模型 Dosages: 40 mg/kg/天 Administration: 口服，每天两次 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	97 mg/mL (199.79 mM)
	Ethanol	97 mg/mL warmed (199.79 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+corn oil	10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Sonidegib (NVP-LDE225) SDF

分子量	485.5
化学式	C₂₆H₂₆F₃N₃O₃
CAS号	956697-53-3
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	Erismodegib

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02358161	Completed	Drug: gemcitabine and nab paclitaxel	Pancreatic Cancer	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\|Novartis\|Celgene Corporation	September 2015	Phase 1\|Phase 2
NCT02254551	Terminated	Drug: LDE225\|Drug: Bortezomib	Multiple Myeloma	SCRI Development Innovations LLC\|Novartis	January 2015	Phase 2
NCT02138929	Completed	Drug: Everolimus\|Drug: LDE 225	Esophageal Cancer	M.D. Anderson Cancer Center\|Novartis\|National Cancer Institute (NCI)	November 10 2014	Phase 1
NCT02195973	Completed	Drug: LDE225	Recurrent Ovarian Cancer	University of Alabama at Birmingham\|Novartis Pharmaceuticals	September 2014	Phase 1
NCT02027376	Completed	Drug: LDE225\|Drug: Docetaxel	Advanced Breast Cancer	Spanish Breast Cancer Research Group\|Novartis	May 2014	Phase 1
NCT02111187	Completed	Drug: LDE225	Prostate Cancer	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	April 2014	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

用于临床的Smoothened抑制剂

LDE225 (NVP-LDE225,Erismodegib) : Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).
最新的Smoothened抑制剂

GANT61 : Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.
Smoothened激活剂

Purmorphamine : Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

研究领域

产品类型

定制您的化合物库

Sonidegib (NVP-LDE225)

客户使用Selleck生产的Sonidegib (NVP-LDE225)发表文献49篇：

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Sonidegib (NVP-LDE225) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

相关Hedgehog/Smoothened产品